Reference number	
1819-H	

SPECIALTY QUANTITY LIMIT PROGRAM

RYDAPT (midostaurin)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit
Rydapt 25 mg capsules	Acute myeloid leukemia: Induction: 50 mg orally twice daily on Days 8 to 21 of each cycle with cytarabine and daunorubicin Consolidation: 50 mg orally twice daily on Days 8 to 21 of each cycle with high-dose cytarabine Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL): 100 mg orally twice daily	224 per 28 days

III. REFERENCES

1. Rydapt [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2017.

Specialty Quantity Limit Rydapt P2017a.docx

© 2017 CVS Caremark. All rights reserved.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of